Selecta, JDRF and Sanofi Extend Collaboration to Develop a Synthetic Vaccine Particle Immunotherapy for Type 1 Diabetes

Selecta, JDRF and Sanofi Extend Collaboration to Develop a Synthetic Vaccine Particle Immunotherapy for Type 1 Diabetes

October 15, 2014

WATERTOWN, Mass.--(Business Wire)--Selecta Biosciences, Inc., and JDRF,

Acceleron Initiates Phase 1 Clinical Trial with Innovative Muscle Drug ACE-083

Acceleron Initiates Phase 1 Clinical Trial with Innovative Muscle Drug ACE-083

October 14, 2014

-- Locally administered investigational therapeutic designed to increase muscle mass in treated muscles --

-- Fourth internally discovered drug expands Acceleron’s clinical pipeline --

Syros Pharmaceuticals’ Scientific Founders Publish New Research on Gene Control Mechanisms

Syros Pharmaceuticals’ Scientific Founders Publish New Research on Gene Control Mechanisms

October 14, 2014

 Papers in Cell and Molecular Cell expand on importance of super-enhancers in regulating gene expression in normal and inflammatory states

WATERTOWN, MA, October 14, 2014 – Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, announced today that recently published research from two of its scientific founders sheds new light on the crucial role of gene control mechanisms in cellular function.

Concert Pharmaceuticals Presents Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-354, Lead Candidate for the Treatment of Spasticity

Concert Pharmaceuticals Presents Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-354, Lead Candidate for the Treatment of Spasticity

October 13, 2014

   No sedation or ataxia observed and treatment was well tolerated

Company plans to initiate a Phase 2 trial this year

Eleven Biotherapeutics Granted U.S. Composition-of-Matter Patent for EBI-005

Eleven Biotherapeutics Granted U.S. Composition-of-Matter Patent for EBI-005

October 7, 2014

- Topically-administered protein therapeutic that blocks IL-1 receptor is in clinical development for dry eye disease and moderate to severe allergic conjunctivitis -

Oasys Water Named to the 2014 Global Cleantech 100

Oasys Water Named to the 2014 Global Cleantech 100

October 7, 2014

List Recognizes the Top Private Companies in Clean Technology

Boston, MA – October 7, 2014: Oasys Water, a world leader in innovative solutions for water treatment and desalination, today announced it was named in the prestigious 2014 Global Cleantech 100, produced by Cleantech Group, whose mission is to connect corporates to sustainable innovation through the i3 market intelligence platform, expert consulting services, and global events.

Seres Health Appoints Two New Board Members

Seres Health Appoints Two New Board Members

October 6, 2014

CAMBRIDGE, Mass., Oct. 6, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced the appointments of Richard N. Kender and Dr. Lorence H. Kim, to the company's board of directors. They each have extensive financial backgrounds which will be beneficial to the Seres team in achieving its business goals.

Visterra Closes $30 Million Series B Financing to Advance Pipeline of Multiple Products for Infectious Diseases

Visterra Closes $30 Million Series B Financing to Advance Pipeline of Multiple Products for Infectious Diseases

October 2, 2014

 – Co-led by New Investors, Merck Research Labs Venture Fund, Vertex Venture Holdings and Temasek –

Eleven Biotherapeutics Announces Top-Line Results from Phase 2 Study of EBI-005 in Patients with Moderate to Severe Allergic Conjunctivitis

Eleven Biotherapeutics Announces Top-Line Results from Phase 2 Study of EBI-005 in Patients with Moderate to Severe Allergic Conjunctivitis

October 2, 2014

 - EBI-005 Demonstrated Statistically Significant Improvements in Ocular Itching, Tearing and Nasal Symptoms in a Conjunctival Allergen Provocation Model -

- Study Does Not Meet Primary Endpoint Using Environmental Exposure Chamber Model -

Avedro Announces Resubmission of New Drug Application to FDA for Corneal Cross-Linking

Avedro Announces Resubmission of New Drug Application to FDA for Corneal Cross-Linking

September 30, 2014

Waltham, Massachusetts, -- Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company announces today that it resubmitted its New Drug Application (NDA) for riboflavin ophthalmic solution/KXL® System to the U.S. Food and Drug Administration (FDA). Avedro anticipates an application action date (PDUFA) in March 2015. This resubmission is a comprehensive reply to questions and requests from the March 2014 complete response letter.